NFKB1 and diffuse large B-cell lymphoma: While there is substantial evidence that aberrant NF-κΒ activation within the lymph node TME, confers worse prognosis in DLBCL, the pharmacological targeting of this interaction has been challenging due to toxicities associated with targeting the canonical NF-κB pathway [56].